Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Ignore The Noise - Novo Nordisk Is A Clear Buy
01:53am, Thursday, 15'th May 2025
Novo Nordisk's stock has declined 55% from its all-time high, but the company continues to report strong quarterly results with significant revenue and profit growth. Despite slowing growth rates and
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies
11:49am, Wednesday, 14'th May 2025
Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targ
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
09:43am, Wednesday, 14'th May 2025
Septerna Inc. SEPN and Novo Nordisk A/S NVO announced an exclusive global collaboration and license agreement on Wednesday.
Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases
07:31am, Wednesday, 14'th May 2025
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
07:04am, Wednesday, 14'th May 2025
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that cou
Why Weight-Loss Developer Stocks Tumbled on Tuesday
07:08pm, Tuesday, 13'th May 2025
Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category dr
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs
08:40am, Tuesday, 13'th May 2025
The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector.
Novo Nordisk: A Strategy With High Potential For Volatile Times
05:12am, Tuesday, 13'th May 2025
Novo Nordisk has a strong economic moat based on significant market shares in diabetes and obesity care, and promising pipeline drugs, though facing competition and political pressures. The company sh
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
06:25pm, Monday, 12'th May 2025
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
12:36pm, Monday, 12'th May 2025
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
12:30pm, Monday, 12'th May 2025
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t
Novo Nordisk: Is obesity wonder drug Wegovy losing its investment appeal?
12:02pm, Monday, 12'th May 2025
Private investors considering Novo Nordisk (NYSE:NVO) should approach with measured optimism. The Danish drugmaker is a global leader in the fast-growing obesity market, but Morgan Stanley believes t
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial
10:46am, Monday, 12'th May 2025
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the firs
Novo Nordisk Stock Is Slumping Today. Here's Why.
08:23am, Monday, 12'th May 2025
Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.
Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now
06:22am, Monday, 12'th May 2025
Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug announ
